A Rat-Derived Hemopressin Peptide Used Different Mechanisms Across Cell and Mouse Effects
A synthesized rat-derived hemopressin peptide produced several effects in cells and mice, but receptor-blocker comparisons did not explain all of them through the same pathway. Reduced movement was especially distinct from the reported CB1-related antinociception.
Rat sequence did not mean a rat behavioral experiment
The peptide was predicted from a rat hemoglobin sequence, synthesized and tested in Neuro 2A cells and mice. It promoted neurite outgrowth through CB1-related signaling in the cell assay. Central administration in mice produced tail-flick antinociception attributed to CB1 rather than CB2 or opioid receptors.
Temperature and movement responses differed
Hypothermia was partly reduced by a CB1 antagonist. Reduced movement after intracerebroventricular administration was insensitive to the cannabinoid and opioid antagonists tested. Those comparisons suggest partly distinct pharmacology rather than showing that every effect was CB1-mediated.
Repeated exposure still produced tolerance
The peptide had limited gastrointestinal transit effects at antinociceptive doses, but repeated intracerebroventricular administration produced antinociceptive tolerance. Limited effects on one endpoint do not establish a broadly safe profile, and direct brain administration is not a practical consumer exposure route.
The study supports further investigation of whether cannabinoid-related antinociception can be separated from other behaviors. It does not demonstrate that separation in patients or establish clinical pain treatment. Species, cell findings, administration route and receptor-specific null comparisons must remain explicit.
Related: interpreting cannabis tolerance claims.
Research cited
Zheng T; Zhang T; Zhang R; Wang ZL; Han ZL; Li N; Li XH; Zhang MN; Xu B; Yang XL; Fang Q; Wang R. Pharmacological characterization of rat VD-hemopressin(α), an α-hemoglobin-derived peptide exhibiting cannabinoid agonist-like effects in mice. Neuropeptides (2017). doi:10.1016/j.npep.2016.12.006. Findings discussed from the study abstract.
